MOSCOW, RUSSIA - Media OutReach - 11 September 2023 - Metalloinvest, a pioneer of green metallurgy in Russia, has opened…
SHANGHAI--(BUSINESS WIRE)--The Shanghai office of international law firm Dorsey & Whitney has moved to a new address: CITIC Square, Suite…
HONG KONG--(BUSINESS WIRE)--#insurance--Despite a sharp increase in catastrophe losses outside their home markets and a challenging investment environment, major Asia-Pacific…
SolarWinds will showcase its product portfolio and speak on how integrated observability and service management solutions help ensure operational resiliency…
ZUG, SWITZERLAND - Media OutReach - 11 September 2023 - pCloud, the leading platform in online storage and data management,…
Today marks 10 years since the European Medicines Agency (EMA) approved the world’s first monoclonal antibody biosimilar infliximab, for all…
Encouraging objective response rate of 52.4% was seen with ifinatamab deruxtecan in heavily pretreated patients IDeate-01 phase 2 trial currently…
An objective response rate of 29.8% was observed with patritumab deruxtecan in heavily pretreated patients BLA submission in U.S. planned…
Daiichi Sankyo and AstraZeneca’s datopotamab deruxtecan plus durvalumab with or without chemotherapy demonstrated objective response rates of 77% and 50%…
Medical professionals and social organizations call for increased awareness of pneumococcal threat and strengthened preventative measures among high-risk individuals HONG…